Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

  title={Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies},
  author={E. Ratti and P. Bettica and Robert Alexander and G. Archer and D. Carpenter and G. Evoniuk and R. Gomeni and Erica L. Lawson and M. L{\'o}pez and H. Millns and E. Rabiner and D. Trist and Michael Trower and S. Zamuner and R. Krishnan and M. Fava},
  journal={Journal of Psychopharmacology},
  pages={424 - 434}
  • E. Ratti, P. Bettica, +13 authors M. Fava
  • Published 2013
  • Psychology, Medicine
  • Journal of Psychopharmacology
  • Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [11C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor… CONTINUE READING
    42 Citations

    Paper Mentions

    Interventional Clinical Trial
    This is a 12-week, randomized, multicenter, double-blind, placebo controlled, fixed-dose parallel group study to assess the efficacy and safety of orvepitant (60 mg/day) versus… Expand
    ConditionsPost-Traumatic Stress Disorder
    InterventionDrug, Other
    Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists
    • 13
    NK1 receptor antagonists for depression: Why a validated concept was abandoned.
    • 17
    Substance P and the Neurokinin-1 Receptor: The New CRF.
    • 22


    Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression
    • 236
    • Highly Influential
    • PDF
    Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
    • 58
    A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    • 103
    • Highly Influential
    Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
    • 151
    Do substance P and the NK1 receptor have a role in depression and anxiety?
    • S. McLean
    • Medicine
    • Current pharmaceutical design
    • 2005
    • 75
    Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.
    • 284
    • PDF